Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

  • Dirk Eyding
  • Monika Lelgemann
  • Ulrich Grouven
  • Martin Härter
  • Mandy Kromp
  • Thomas Kaiser
  • Michaela F Kerekes
  • Martin Gerken
  • Beate Wieseler

Related Research units

Abstract

To assess the benefits and harms of reboxetine versus placebo or selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression, and to measure the impact of potential publication bias in trials of reboxetine.

Bibliographical data

Original languageGerman
ISSN0959-535X
Publication statusPublished - 2010
pubmed 20940209